Core Viewpoint - Tianan Health (00383) announced that Dr. Wang Yongquan will succeed Mr. Jiang Muxian as the chairman of the nomination committee starting from August 1, 2025, while Mr. Jiang will remain a member of the nomination committee [1] Group 1 - Dr. Wang Yongquan is currently a member of the company's nomination committee [1] - Mr. Jiang Muxian will continue to serve as a member of the nomination committee after his transition [1]

Core Viewpoint - Tianan Health (00383) reported a decline in revenue and profit for the six months ending June 30, 2025, primarily due to decreased operational income in the medical segment and increased non-cash fair value losses on investment properties [1] Financial Performance - The company achieved revenue of HKD 783 million, representing a year-on-year decrease of 4.67% [1] - Profit attributable to shareholders was HKD 11.979 million, down 44.69% year-on-year [1] - Basic earnings per share were HKD 0.0111 [1] Contributing Factors - The decline in revenue and profit was mainly attributed to reduced operational income in the medical segment [1] - There was an increase in non-cash fair value losses on investment properties [1] - The decrease in employee benefit expenses and the recognition of unrealized foreign exchange gains offset some losses [1] - The company experienced a reduction in income tax expenses compared to the first half of 2024, which also contributed to mitigating the overall decline [1]

Core Viewpoint - Tian Andru Health (00383) announced that Dr. Wang Yongquan will succeed Mr. Jiang Muxian as the Chairman of the Nomination Committee starting from August 1, 2025, while Mr. Jiang will remain a member of the committee [1] Group 1 - Dr. Wang Yongquan is currently a member of the company's Nomination Committee [1] - Mr. Jiang Muxian will continue to serve as a member of the Nomination Committee after his transition [1]

Core Viewpoint - Tianan Health (00383.HK) reported a total revenue of HKD 783 million for the six months ending June 30, 2025, representing a year-on-year decrease of approximately 4.67% [1] - The profit attributable to shareholders was HKD 11.979 million, a decline of about 44.69% compared to the previous year [1] - Basic earnings per share were HKD 0.0111, down from HKD 0.0199 in the first half of 2024 [1] Revenue and Profit Analysis - The decrease in revenue was primarily due to a reduction in operating income from the medical segment [1] - The company experienced an increase in non-cash fair value losses on investment properties [1] - However, this decline was partially offset by a reduction in employee benefit expenses, recognition of unrealized foreign exchange gains, and a decrease in income tax expenses [1]

FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00028 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,466,069,491 | | 0 | | 1,466,069,491 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 1,466,069,491 | | 0 | | 1,466,069,491 | 第 2 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 天安中國投資有限公司 (「本公司」) 呈交日 ...

Group 1 - Tianan Holdings (00028.HK) closed at HKD 4.680 on August 1, marking a 2.63% increase from the previous trading day, with an intraday high of HKD 4.720, reaching a nearly one-year high [1] - On the same day, the net inflow of funds was HKD 46.59 thousand, with no significant inflow or outflow from major investors [2] Group 2 - Tianan China Investment Company is an investment holding company established in Hong Kong in 1986, and it was one of the first Chinese concept companies listed on the Hong Kong Stock Exchange in 1987 [2] - The company's main business activities include the development of residential, villa, office, and commercial properties in mainland China, as well as property investment and management in Hong Kong [2]

人民财讯8月1日电，阿斯利康8月1日宣布，伟立瑞(英文商品名：Ultomiris，通用名：瑞利珠单抗注射 液)在中国正式获批用于治疗抗水通道蛋白4(AQP4)抗体阳性的成人视神经脊髓炎谱系疾病(NMOSD)患 者。 ...

Group 1 - The company announced an adjustment in the conversion price of its convertible bonds due to the repurchase and cancellation of restricted stocks, changing from RMB 7.51 per share to RMB 7.52 per share, effective from August 4, 2025 [1][4] - The company issued 29 million convertible bonds with a total value of RMB 2.9 billion on March 16, 2023, with a maturity period of six years [1] - The company will repurchase and cancel 579,780 restricted stocks, which account for 0.23% of the total share capital, due to the failure to meet performance targets for the third vesting period of the incentive plan [2][3] Group 2 - The adjustment formula for the conversion price of the convertible bonds is based on the issuance of new shares or stock dividends, with the new price calculated as P1 = (P0 + A × k) / (1 + k) [3] - The adjusted conversion price reflects a minor increase, indicating a slight dilution effect from the repurchase of restricted stocks [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：601666 证券简称：平煤股份 编号：2025-060 平顶山天安煤业股份有限公司 第九届董事会第四十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 平顶山天安煤业股份有限公司（以下简称"公司"）第九届董事会第四十五次会议于2025年7月23日以书 面、短信或电子邮件的方式发出通知，于2025年7月28日采用通讯表决的方式召开，会议由公司董事长 焦振营先生主持。本次会议应表决董事15人，实际表决董事15人。会议召开及程序符合《公司法》等法 律、法规及《公司章程》的有关规定。经与会董事审议，本次董事会会议通过如下事项： 一、关于出售控股子公司股权的议案 会议以15票同意，0票反对，0票弃权，审议通过该议案。（内容详见2025-061号公告） 三、关于开展"平顶山天安煤业股份有限公司煤矿数字化智能化改造提升项目（2024-2026年）"贷款的 议案 会议以15票同意，0票反对，0票弃权，审议通过该议案。（内容详见2025-062号公告） 四、关于 ...

Group 1 - The core issue is that Tianan Di Heng Asset Management Co., Ltd. has been ordered to rectify multiple problems in its private fund business activities as per the announcement from the Shanxi Regulatory Bureau of the China Securities Regulatory Commission on July 29, 2025 [1] - The company lacks independence in personnel and office space, and has not implemented effective internal controls [1] - The fund registration information submitted to the Asset Management Association of China is found to be untrue and inaccurate [1] - The company is engaged in activities unrelated to private fund management [1] - There are issues with the authenticity of shareholder contributions [1] - These actions violate the Interim Measures for the Supervision and Administration of Private Investment Funds, specifically Article 4, Paragraph 1, and Article 25, Paragraph 1 [1]